Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension. GNH USA supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monoprost, a prostaglandin analog, is used to manage conditions that involve elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers eye pressure to prevent development of glaucoma.

Latanoprost may cause ocular and systemic reactions. Patients should be aware of both frequent and less common events.

Common Side Effects: - Eye redness or hyperemia - Increased eyelash length and thickness - Darkening of the iris color - Eye irritation or foreign‑body sensation - Blurred vision - Mild eye pain or discomfort

Serious or Rare Side Effects: - Severe allergic reaction (e.g., swelling, rash) - Uveitis or intra‑ocular inflammation - Macular edema leading to vision changes - Sudden loss of vision - Ocular infection - Persistent eye pain requiring medical attention

Before initiating therapy, clinicians should consider several safety aspects. - Monitor intra‑ocular pressure: schedule regular measurements to assess efficacy. - Assess for ocular infection: avoid use if active infection is present. - Avoid use in active ocular inflammation: may exacerbate the condition. - Use with caution in patients with a history of herpetic eye disease. - Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Concomitant use of other prostaglandin analog eye drops: increased risk of additive side effects. - Use with non‑steroidal anti‑inflammatory eye drops: may diminish IOP‑lowering effect.

Moderate Interactions (Monitor Closely):\n- Beta‑blocker eye drops: additive intra‑ocular pressure reduction. - Topical corticosteroids: potential reduction in therapeutic response. - Systemic antihistamines: may affect ocular surface tolerance.